J. Laurin et al., URSODEOXYCHOLIC ACID OR CLOFIBRATE IN THE TREATMENT OF NON-ALCOHOL-INDUCED STEATOHEPATITIS - A PILOT-STUDY, Hepatology, 23(6), 1996, pp. 1464-1467
Non-alcohol-induced steatohepatitis (NASH) is characterized by elevate
d serum aminotransferase activities with hepatic steatosis, inflammati
on, and occasionally fibrosis that may progress to cirrhosis. No estab
lished treatment exists for this potentially serious disorder. Our aim
was to conduct a pilot study to evaluate the safety and estimate the
efficacy of ursodeoxycholic acid (UDCA) and clofibrate in the treatmen
t of NASH. Forty patients were diagnosed with NASH based on a compatib
le Liver biopsy with other causes of liver disease, including alcohol
abuse, excluded by history, serum tests, and use of ultrasound. Twenty
-four patients received 13 to 15 mg/kg/d of UDCA for 12 months, Sixtee
n patients with hypertriglyceridemia were placed on clofibrate, 2 g/da
y for 12 months, Twenty-five women and 15 men entered the study. Six o
f 40 patients (15%) withdrew because of side effects. Four additional
patients were withdrawn because of noncompliance; one of them later re
quired liver transplantation. In the UDCA group, the decreases in mean
serum levels of alkaline phosphatase, alanine transaminase (ALT), and
gamma-glutamyl transpeptidase (GGT) as well as histological grade of
steatosis were significant. Among the patients treated with clofibrate
, no change from baseline was found in mean ALT, aspartate transaminas
e (AST), GGT, bilirubin, triglycerides, and cholesterol, or in histolo
gical. grade of steatosis, inflammation, or fibrosis after 12 months o
f treatment as compared with entry, Alkaline phosphatase activities de
creased significantly from baseline. Despite the known lipid-lowering
effects of clofibrate, it did not appear to be of clinical benefit in
the treatment of NASH in this 1-year pilot study. However, treatment o
f NASH with UDCA for 12 months resulted in significant improvement in
alkaline phosphatase, ALT, GGT, and hepatic steatosis. The possible be
nefit of UDCA therapy should be further investigated in the context of
a randomized, controlled trial.